5 completed, 1 terminated. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow recombinant factor XIII-A2: new trials by email Literature Review of recombinant factor XIII-A2 trials Research Report on recombinant factor XIII-A2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan recombinant factor XIII - Congenital Bleeding Disorder, Congenital FXIII Deficiency | Completed | Novo Nordisk A/S | 8 | 2016-03-16 | 2025-08-29 | |
| Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study catridecacog - Congenital Bleeding Disorder, Congenital FXIII Deficiency | Completed | Novo Nordisk A/S | 30 | 2013-05-17 | 2019-07-09 | |
| A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis catridecacog, placebo - Inflammation, Ulcerative Colitis | Phase 2 | Terminated | Novo Nordisk A/S | 20 | 2012-10-01 | 2014-10-02 |
| Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency catridecacog - Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 6 | 2011-01-01 | 2016-06-24 |
| Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects catridecacog, recombinant factor XIII - Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 51 | 2010-03-01 | 2016-09-21 |
| Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 catridecacog - Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 63 | 2009-09-21 | 2018-01-24 |
Colitis, Ulcerative (1) · Inflammation (1)
Novo Nordisk A/S (6)
United Kingdom (4) · United States (3) · Canada (2) · Hungary (2) · Israel (2) · Italy (2) · Japan (2) · Spain (2) · Austria (1) · Bulgaria (1) · Croatia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1)
PMID 25263390, PMID 25643920, PMID 28581691, PMID 37883802
2008 (1), 2009 (1)